CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mersana Therapeutics, Inc., today announced that Anna Protopapas, President and Chief Executive Officer, will present a company overview at the Cowen and Company 37th Annual Health Care Conference at the Boston Marriott Copley Place in Boston on Monday, March 6, 2017, from 3:00 -3:25pm EST.
About Mersana Therapeutics
Mersana Therapeutics is a biotechnology company with highly differentiated and proprietary immunoconjugate platforms that allow for significantly higher drug loads, providing greater efficacy while simultaneously increasing tolerability. As a result, our platforms create expanded opportunities to deliver meaningful clinical benefit to patients. Our lead program, XMT1522, is in Phase I clinical trials. Our second program, XMT1536, will be entering clinical trials in the latter part of 2017. In addition, our partners are advancing their pipeline of immunoconjugates using our platforms.